This product has been identified as a dietary supplement that does not meet Food and Drug Administration (FDA) labeling requirements

The notice arrives naming a specific standard, which is unusual and useful:

This product has been identified as a dietary supplement that does not meet Food and Drug Administration (FDA) labeling requirements. We have determined that the amount of botanical extract per serving on the label is inaccurate and/or misleading. Labeling recommendations for botanical extracts shall be according to criteria described in 21 CFR 101.36 and/or USP <565> Botanical Extracts. Amazon policy prohibits dietary supplement products that do not meet FDA labeling requirements. Violations of this policy may result in the deactivation of your selling account.

Note the last sentence. This one carries account-level language, which the ingredient-field notices do not. Treat it as more serious than a routine listing flag.

What has almost certainly happened

In the great majority of cases this is about extract ratios.

You sell a 200mg turmeric extract at a 10:1 concentration. The marketing convention in the category is to express that as “2000mg equivalent”, and often just as “2000mg”. Your Supplement Facts panel, correctly, says 200mg.

Amazon compares the two and sees a listing claiming ten times what the panel declares. That is the “inaccurate and/or misleading” it is describing. The extraction ratio may be entirely genuine — that is not the point being made.

The same failure appears with:

• Proprietary blends where individual ingredient amounts are implied but not declared
• Per-bottle totals presented as per-serving amounts
• Rounded-up figures that do not match the panel exactly
• Standardised extracts where the marker compound percentage is stated as the total

Why arguing does not work

There is no substantiation exception in the policy. Amazon does not evaluate whether your 10:1 ratio is real, whether your supplier’s documentation supports it, or whether the convention is standard across the category. It compares two numbers.

If a number is not on the Supplement Facts panel, it should not appear in the listing. That is the entire test, and appeals that explain conversion mathematics are the most common way sellers lose another week.

The fix

1. Pull the Supplement Facts panel and treat it as the single source of truth for every quantity.
2. Find every stated amount across the listing — title, bullets, description, A+ content, backend fields, and any figure baked into an image or infographic. Image text is read.
3. Make them match the panel exactly. State the actual extract weight. Where you want to convey concentration, express it as a ratio alongside the true amount — “200mg turmeric extract (10:1)” — rather than as an equivalent-weight headline number.
4. Check the variations. Children sharing the root violation stay suppressed even after the parent is clean.
5. Appeal, describing precisely which figures you corrected and where.

If you cannot edit the listing

A frustrating and common wrinkle: sellers receive this notice, understand exactly what needs changing, and then cannot make the change because the deactivated listing throws an error — error 5665 being the one that comes up most.

The demand and the ability to comply are in conflict, and Seller Support does not always connect the two.

• Submit by flat file rather than the listing editor. The two write paths behave differently, and the flat file often succeeds where the UI is blocked.
• If the flat file is blocked too, open one case that states both facts together: the notice requiring the edit, and the specific error code preventing it. Cases that mention only one of the two get answered as if the other did not exist.
• Do not let the clock run while you retry the editor. This notice carries account-level language, and silence reads as non-compliance.

When the number is on the pack

Everything above assumes the inflated figure lives in your listing. If “2000mg” is printed on the physical label, this stops being a catalogue fix and becomes a relabelling project — new artwork, new production run, and an interim period where the product cannot be sold under accurate claims.

Resist the tempting shortcut of updating the Supplement Facts panel image to match the inflated claim. That moves the problem off Amazon and onto your physical product, creating FDA labelling exposure under 21 CFR 101 that is materially worse than a suspended listing.

The wider pattern

Amazon’s supplement enforcement is, at bottom, a consistency check between what your label declares and what your listing claims. It does not assess whether your product is good, safe or accurately manufactured. It checks whether two documents agree — and gives no credit for the industry conventions that make them disagree.

Keep reading: What actually triggers a supplement listing suppression · The anatomy of a 75-character supplement title · Reinstating after a cGMP deactivation